The Clayton Foundation Laboratories for Peptide Biology, The Salk Institute, La Jolla, California 92037, USA
Address for correspondence: Catherine Rivier, Ph. D., The Salk Institute, 10010 N. Torrey Pines Road, La Jolla, CA 92037. Voice: 858-453-4100; fax: 858-552-1546.
crivier{at}salk.edu
Ann. N.Y. Acad. Sci. 992: 72-85 (2003).
This work examines the role of nitric oxide (NO) in the periphery
(i.e., on the pituitary) and the brain (particularly on corticotropin-releasing
factor [CRF] and vasopressin [VP] neurons in the paraventricular
nucleus [PVN] of the hypothalamus) as a modulator of the ACTH
response to lipopolysaccharide. We previously showed that NO
restricted the pituitary response to VP while it facilitated
the synthesis of PVN CRF and VP. In our experience, only relatively
high doses of lipopolysaccharide (>50 µg/kg, injected
intravenously [iv]) cause detectable increases in PVN neuronal
activation. Our hypothesis, therefore, was that pituitary NO-VP
interactions would predominate in rats injected with a low dose
of lipopolysaccharide (0.5 µg/kg, iv) while the stimulatory
influence of the gas on PVN neuronal activity would play an
important role following iv injection of a large dose of lipopolysaccharide
(50 µg/kg, iv). We observed that the ability of 0.5 µg/kg
lipopolysaccharide to release ACTH was significantly enhanced
by the subcutaneous (sc), but not the intracerebroventricular
(icv) injection of L-NAME, an arginine derivative that blocks
NO synthesis. The effect of sc L-NAME was reversed by immunoneutralization
of endogenous VP, which indicated that in this model, the ability
of lipopolysaccharide to release ACTH depended, at least in
part, on the influence exerted by NO on the pituitary response
to VP. In rats injected with the high lipopolysaccharide dose,
the sc injection of L-NAME decreased plasma ACTH levels compared
to those in rats pretreated with the vehicle. The effect of
sc L-NAME was not significantly altered by VP antibodies. These
results indicate that in this model, the primary influence of
NO was exerted in the PVN and/or its afferents and that it did
not depend on a peripheral, VP-mediated effect of the gas. On
the one hand, these data are at odds with our finding that the
icv injection of L-NAME only marginally altered the ACTH response
to the large dose of lipopolysaccharide. As icv injected L-NAME
should have primarily decreased hypothalamic, but not pituitary
NOS, its only modest influence on ACTH release may have been
due to a balance between stimulating and inhibiting effects
of NO within the brain. As high doses of lipopolysaccharide
increase brain levels of prostaglandin, monoamine, and proinflammatory
cytokines, it will be important to investigate the influence
exerted by NO on these secretagogues and on their interactions
with PVN CRF and VP neurons, which may help us resolve the issues
raised by our results. Collectively, these data support our
hypothesis that the mechanisms mediating the ACTH response to
a low lipopolysaccharide concentration involve the inhibitory
VP-mediated influence of NO on pituitary activity. By contrast,
the stimulatory effect of high doses of lipopolysaccharide on
ACTH release depends, at least in part, on the ability of NO
to upregulate PVN neuronal activity.